Anti-CD19/CD20/CD22 CAR T-Cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anti-CD19/20/22 Chimeric Antigen Receptor T-Cells, CD19/CD20/CD22-targeted CAR-T Cells

Filter by location:

Columbus, Ohio1 trial

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Nationwide Children's Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.